ArticleEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society2026
From single to dual platelet inhibition FIBTEM assay: fibrinogen replacement thresholds for critical bleeding after trauma.
Article in European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe FIBTEM assay in Rotational Thromboelastometry (ROTEM
methodsIn this retrospective cohort study, we included adult patients with major trauma across Queensland who presented between 2022 and 2025 and had results available for paired ROTEM and conventional coagulation tests on arrival. Patients were sub-grouped into single and dual-platelet inhibition assay groups. Correlations between FIBTEM-A5 and Clauss fibrinogen were analysed, comparing correlation strength and diagnostic accuracy for fibrinogen levels of < 2.0 g/L.
resultsThe relationship between FIBTEM-A5 and Clauss fibrinogen was similar using single platelet inhibition assays (R² 0.61;95%CI: 0.51-0.70) and dual-platelet inhibition assays (R² 0.70;95%CI: 0.62-0.77; p = 0.94). Predicted FIBTEM-A5 amplitudes at 2 g/L fibrinogen were 7.83 mm (95%CI: 7.42-8.23) and 7.54 mm (95%CI: 7.22-7.87). Diagnostic performance for detecting fibrinogen < 2.0 g/L was comparable between assays, for both FIBTEM-A5 ≤ 10 mm and FIBTEM-A5 ≤ 8 mm (all p > 0.05). For the dual-platelet inhibition assay, sensitivity and specificity were 97.8% and 48.1% at ≤ 10 mm, and 92.1% and 74.7% at ≤ 8 mm.
conclusionDual-platelet inhibition did not alter the relationship between FIBTEM-A5 and Clauss fibrinogen or the diagnostic accuracy of FIBTEM thresholds for identifying hypofibrinogenemia. FIBTEM-A5 ≤ 10 mm maintained high sensitivity, while ≤ 8 mm demonstrated greater specificity. Recalibration of established FIBTEM thresholds is not required following transition to dual-platelet inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.